Sign up to save your podcasts
Or
Share Drug Discovery Targeting Drug-Resistant Bacteria
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Drug Discovery Targeting Drug-Resistant Bacteria
A comprehensive overview of the global challenge of antibiotic resistance (AMR) and the drug discovery efforts underway to combat it. It details the dwindling pipeline of new antibiotics, particularly those effective against multidrug-resistant (MDR) Gram-negative bacteria, and outlines established and novel mechanisms of antibacterial action and resistance, such as enzyme modification and target site mutations. A significant portion of the text discusses new strategies for drug development, including the use of bacteriophage-derived products like lysins (e.g., P128), and the repurposing of existing non-antibiotic drugs for antibacterial and antiviral uses. The documents also address the unique challenges and screening platforms for developing medical countermeasures against biothreat agents, frequently emphasizing the role of combination therapy and host-directed therapies (HDT) in treating resistant infections like those caused by Mycobacterium tuberculosis and Staphylococcus aureus.
You can listen and download our episodes for free on more than 10 different platforms:
https://linktr.ee/pharmacy_simple
Produced by:
https://www.podcaistudio.com/
You can listen and download our episodes for free on more than 10 different platforms:
https://linktr.ee/pharmacy_simple
Produced by:
https://www.podcaistudio.com/
View all episodes
By Pharmacy Made SimpleA comprehensive overview of the global challenge of antibiotic resistance (AMR) and the drug discovery efforts underway to combat it. It details the dwindling pipeline of new antibiotics, particularly those effective against multidrug-resistant (MDR) Gram-negative bacteria, and outlines established and novel mechanisms of antibacterial action and resistance, such as enzyme modification and target site mutations. A significant portion of the text discusses new strategies for drug development, including the use of bacteriophage-derived products like lysins (e.g., P128), and the repurposing of existing non-antibiotic drugs for antibacterial and antiviral uses. The documents also address the unique challenges and screening platforms for developing medical countermeasures against biothreat agents, frequently emphasizing the role of combination therapy and host-directed therapies (HDT) in treating resistant infections like those caused by Mycobacterium tuberculosis and Staphylococcus aureus.
You can listen and download our episodes for free on more than 10 different platforms:
https://linktr.ee/pharmacy_simple
Produced by:
https://www.podcaistudio.com/
You can listen and download our episodes for free on more than 10 different platforms:
https://linktr.ee/pharmacy_simple
Produced by:
https://www.podcaistudio.com/